11/10/2009 1:30:58 PM
SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (Pink Sheets:OVIT) reported today that two of its proprietary products, the AdnaTest™ BreastCancer and AdnaTest EMT1/StemCell, were evaluated in Germany by the Departments of Gynecology and Obstetrics and Internal Medicine (Cancer Research) at University Hospital Essen, University of Duisburg-Essen and the Department of Gynecology and Obstetrics, University Hospital of Tuebingen. The research report of those findings has been accepted for publication in the prestigious publication, Cancer Research. The Company’s AdnaTest™ BreastCancer product developed and produced by OncoVista’s wholly owned German subsidiary AdnaGen AG, is presently commercially available and CE marked in Europe.
comments powered by